Bioqual AI Stock Analysis
Want to see BIOQ full AI Analyst Report?
Bioqual (BIOQ) AI Stock Analysis
Bioqual
(Other OTC:BIOQ)
BIOQ scores low primarily due to weakened financial performance: persistent losses, very low profitability, negative free cash flow, and higher leverage. Technicals also lean bearish with price below major moving averages and negative MACD, while valuation is constrained by negative earnings (negative P/E) and no stated dividend yield.
Bioqual (BIOQ) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $27.73M
- Dividend Yield
- ―
- Average Volume (3M)
- 557
- Price to Earnings (P/E)
- -6.3
- Beta (1Y)
- -0.19
- Revenue Growth
- -14.30%
- EPS Growth
- -610.16%
- Country
- US
- Employees
- 278
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Bioqual Business Overview & Revenue Model
Company Description
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans numerou...
Bioqual Financial Statement Overview
Summary
Despite a strong TTM revenue rebound (+73.4%), profitability is weak (gross profitability ~3.6%) with a return to losses (TTM net margin ~-10.4%). Cash flow has deteriorated to slightly negative operating cash flow and negative free cash flow, and leverage has increased to roughly 1.0x debt-to-equity, raising financial risk if losses persist.
Income Statement
24NegativeBalance Sheet
38NegativeCash Flow
27Negative| Breakdown | TTM | Aug 2025 | Aug 2024 | Aug 2023 | May 2023 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.24M | 39.95M | 48.87M | 58.59M | 62.66M | 66.15M |
| Gross Profit | 1.05M | 1.43M | -1.90M | 7.43M | 12.60M | 13.01M |
| EBITDA | -1.56M | -2.25M | 473.97K | 3.03M | 6.97M | 14.76M |
| Net Income | -4.41M | -4.17M | -1.05M | 483.48K | 835.55K | 5.26M |
Balance Sheet | ||||||
| Total Assets | 67.41M | 68.44M | 57.12M | 56.59M | 61.32M | 63.34M |
| Cash, Cash Equivalents and Short-Term Investments | 16.47M | 16.01M | 17.85M | 15.59M | 7.28M | 2.18M |
| Total Debt | 31.92M | 32.71M | 16.54M | 3.59M | 18.61M | 18.72M |
| Total Liabilities | 35.46M | 36.04M | 20.96M | 18.94M | 23.70M | 25.67M |
| Stockholders Equity | 31.95M | 32.41M | 36.15M | 37.65M | 37.61M | 37.67M |
Cash Flow | ||||||
| Free Cash Flow | -650.68K | -66.78K | 2.71M | 8.76M | 5.99M | -4.57M |
| Operating Cash Flow | -165.45K | 351.44K | 2.94M | 9.36M | 8.23M | 313.36K |
| Investing Cash Flow | -7.46M | -7.08M | -238.78K | -597.13K | -2.24M | -4.73M |
| Financing Cash Flow | 0 | 0 | -447.21K | -447.21K | -894.42K | -1.12M |
Bioqual Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOQ, the sentiment is Negative. The current price of 30.25 is below the 20-day moving average (MA) of 31.46, below the 50-day MA of 32.83, and below the 200-day MA of 34.67, indicating a bearish trend. The MACD of -0.87 indicates Positive momentum. The RSI at 24.49 is Positive, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOQ.
Bioqual Peers Comparison
Overall Rating
PRPO56Neutral
BNGO51Neutral
VNRX45Neutral
BDSX44Neutral- BIOQ43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PRPO | 56Neutral | $42.34M | -41.02 | -7.84% | ― | 21.76% | 22.97% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BNGO | 51Neutral | $17.19M | -0.41 | -85.00% | ― | 8.23% | 82.76% |
| VNRX | 45Neutral | $5.15M | -0.05 | 77.10% | ― | 86.32% | 21.31% |
| BDSX | 44Neutral | $111.11M | -3.67 | -442.34% | ― | 31.23% | 48.56% |
| BIOQ | 43Neutral | $27.04M | -6.29 | -13.07% | ― | -14.30% | -610.16% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BIOQ | Bioqual | 30.25 | -8.26 | -21.45% | |
| VNRX | VolitionRX Ltd. | 0.20 | -6.89 | -97.14% | |
| PRPO | Precipio | 24.80 | 5.28 | 27.05% | |
| BNGO | Bionano Genomics | 1.10 | -0.37 | -25.17% | |
| BDSX | Biodesix, Inc. | 10.12 | 2.22 | 28.10% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026